Laurent Fauchier1, Nicolas Clementy2, Arnaud Bisson2, Karim Stamboul3, Fabrice Ivanes2, Denis Angoulvant2, Dominique Babuty2, Gregory Y H Lip4,5. 1. Service de Cardiologie et Laboratoire d'Electrophysiologie Cardiaque, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Université François Rabelais, 37044, Tours, France. lfau@med.univ-tours.fr. 2. Service de Cardiologie et Laboratoire d'Electrophysiologie Cardiaque, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Université François Rabelais, 37044, Tours, France. 3. Service de Cardiologie, Centre Hospitalier Universitaire de Dijon et Université de Bourgogne, Dijon, France. 4. University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK. 5. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Abstract
BACKGROUND: Atrial fibrillation (AF) may be related to acute and temporary causes, whether cardiovascular or non-cardiovascular. It remains unclear whether the risk of ischemic stroke is different in this setting, and whether antithrombotic management should be different in these patients. The objective of the study was to describe and compare the risk of stroke in AF patients with and with no such temporary precipitating cause. METHODS: Among 8962 patients with AF seen between 2000 and 2010, we focused our analysis on 4587 patients with non-permanent AF, of whom 740 (16 %) had at least one possible temporary cause of AF. RESULTS: During a mean follow-up of 944 days (median 451, interquartile range 8-1624), the adjusted rates of stroke/TE were non-significantly different between patients with a temporary cause of AF and other AF patients (HR = 1.08, 95 % CI 0.82-1.41, p = 0.59 after adjustment on age, gender, CHA2DS2VASc score, OAC use and antiplatelet therapy use). Cardiovascular mortality was higher in patients with a temporary cause when compared to other AF patients (adjusted HR = 1.42, 95 % CI 1.08-1.86, p = 0.01). In patients with a temporary cause of AF, prescription of oral anticoagulation was independently associated with a better prognosis for cardiovascular death/stroke/thromboembolism (HR = 0.44, 95 % CI 0.29-0.67, p = 0.0001). CONCLUSION: AF patients with presumed temporary cause of AF had a similar risk of stroke/thromboembolism and a worse prognosis for cardiovascular mortality than other AF patients. Use of oral anticoagulation was associated with a better prognosis in these patients.
BACKGROUND:Atrial fibrillation (AF) may be related to acute and temporary causes, whether cardiovascular or non-cardiovascular. It remains unclear whether the risk of ischemic stroke is different in this setting, and whether antithrombotic management should be different in these patients. The objective of the study was to describe and compare the risk of stroke in AFpatients with and with no such temporary precipitating cause. METHODS: Among 8962 patients with AF seen between 2000 and 2010, we focused our analysis on 4587 patients with non-permanent AF, of whom 740 (16 %) had at least one possible temporary cause of AF. RESULTS: During a mean follow-up of 944 days (median 451, interquartile range 8-1624), the adjusted rates of stroke/TE were non-significantly different between patients with a temporary cause of AF and other AFpatients (HR = 1.08, 95 % CI 0.82-1.41, p = 0.59 after adjustment on age, gender, CHA2DS2VASc score, OAC use and antiplatelet therapy use). Cardiovascular mortality was higher in patients with a temporary cause when compared to other AFpatients (adjusted HR = 1.42, 95 % CI 1.08-1.86, p = 0.01). In patients with a temporary cause of AF, prescription of oral anticoagulation was independently associated with a better prognosis for cardiovascular death/stroke/thromboembolism (HR = 0.44, 95 % CI 0.29-0.67, p = 0.0001). CONCLUSION:AFpatients with presumed temporary cause of AF had a similar risk of stroke/thromboembolism and a worse prognosis for cardiovascular mortality than other AFpatients. Use of oral anticoagulation was associated with a better prognosis in these patients.
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: Karl Georg Haeusler; Klaus Gröschel; Martin Köhrmann; Stefan D Anker; Johannes Brachmann; Michael Böhm; Hans-Christoph Diener; Wolfram Doehner; Matthias Endres; Christian Gerloff; Hagen B Huttner; Manfred Kaps; Paulus Kirchhof; Darius Günther Nabavi; Christian H Nolte; Waltraud Pfeilschifter; Burkert Pieske; Sven Poli; Wolf Rüdiger Schäbitz; Götz Thomalla; Roland Veltkamp; Thorsten Steiner; Ulrich Laufs; Joachim Röther; Rolf Wachter; Renate Schnabel Journal: Clin Res Cardiol Date: 2018-04-27 Impact factor: 5.460
Authors: D Duerschmied; J Brachmann; H Darius; N Frey; H A Katus; W Rottbauer; A Schäfer; H Thiele; C Bode; Uwe Zeymer Journal: Clin Res Cardiol Date: 2018-04-20 Impact factor: 5.460
Authors: William F McIntyre; Pablo A Mendoza; Emilie P Belley-Côté; Richard P Whitlock; Kevin J Um; Natalie Maystrenko; P J Devereaux; David Conen; Jorge A Wong; Stuart J Connolly; Jeff S Healey Journal: Clin Cardiol Date: 2018-10-18 Impact factor: 2.882
Authors: A Gundlund; Thomas Kümler; Anders Nissen Bonde; Jawad Haider Butt; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Lars Køber; Jonas Bjerring Olesen; Emil Loldrup Fosbøl Journal: BMJ Open Date: 2019-09-20 Impact factor: 2.692